Key updates on Down syndrome community access to new Alzheimer’s drugs
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels to break down the barriers that currently prevent people with […]
LuMind IDSC statement on FDA approval of Leqembi
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease July 7, 2023 In a groundbreaking decision that signals new hope for people with Alzheimer’s […]
MapHabit Study: Assistive Technology Has Positive Outcomes for Children with Down Syndrome
Study Finds Assistive Technology Has Positive Outcomes for Children with Down Syndrome and Their Caregivers In partnership with the LuMind IDSC Foundation (LuMind IDSC), MapHabit, a neuroscience-based assistive technology (AT) […]
Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s disease, a group of international experts are calling for modification […]
LuMind IDSC Statement re: Donanemab Phase 3 Results
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly slowed cognitive and functional decline in people with early symptomatic […]
Important progress in the treatment of sleep apnea and Down syndrome
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve Stimulator for children with Down Syndrome and significant sleep apnea who are 13 years and […]
Fierce Biotech article highlights dearth of inclusion in Alzheimer’s research
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An important article from industry publication Fierce Biotech highlights the lack […]
With support from Lilly, LuMind IDSC launches key research and awareness activities to advance Down syndrome research
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration with Eli Lilly and Company (Lilly) aimed at accelerating research […]
Results from “Challenges of Caregiving” Survey Published in Research Journal
The LuMind IDSC community and caregivers across the U.S. participated in “Challenges of Caregiving,” an online survey of caregiver perspectives on a range of topics that are important to the […]
New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for an antibody drug candidate called lecanemab. (Read more about the development of lecanemab here.) An […]